Peer Review reports
From: Efficacy of low-dose rituximab in minimal change disease and prevention of relapse
| Original Submission | ||
|---|---|---|
| 25 Jun 2022 | Submitted | Original manuscript |
| 28 Jul 2022 | Reviewed | Reviewer Report |
| 29 Jul 2022 | Reviewed | Reviewer Report |
| 13 Aug 2022 | Author responded | Author comments - Zhigang Ma |
| 17 Aug 2022 | Author responded | Author comments - Zhigang Ma |
| Resubmission - Version 2 | ||
| 13 Aug 2022 | Submitted | Manuscript version 2 |
| 21 Aug 2022 | Author responded | Author comments - Zhigang Ma |
| Resubmission - Version 3 | ||
| 21 Aug 2022 | Submitted | Manuscript version 3 |
| 5 Sep 2022 | Reviewed | Reviewer Report |
| 28 Sep 2022 | Reviewed | Reviewer Report |
| 6 Oct 2022 | Author responded | Author comments - Zhigang Ma |
| Resubmission - Version 4 | ||
| 6 Oct 2022 | Submitted | Manuscript version 4 |
| 11 Nov 2022 | Reviewed | Reviewer Report |
| 1 Dec 2022 | Reviewed | Reviewer Report |
| 19 Dec 2022 | Author responded | Author comments - Zhigang Ma |
| Resubmission - Version 5 | ||
| 19 Dec 2022 | Submitted | Manuscript version 5 |
| 22 Dec 2022 | Author responded | Author comments - Zhigang Ma |
| Resubmission - Version 6 | ||
| 22 Dec 2022 | Submitted | Manuscript version 6 |
| 12 Jan 2023 | Reviewed | Reviewer Report |
| Resubmission - Version 7 | ||
| Submitted | Manuscript version 7 | |
| Publishing | ||
| 20 Feb 2023 | Editorially accepted | |
| 26 Apr 2023 | Article published | 10.1186/s12882-023-03092-7 |
You can find further information about peer review here.